Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a

被引：108

作者：

Pohl, D ^{[1
]}

Rostasy, K ^{[1
]}

Gärtner, J ^{[1
]}

Hanefeld, F ^{[1
]}

机构：

[1] Univ Gottingen, Dept Pediat & Pediat Neurol, D-37075 Gottingen, Germany

来源：

NEUROLOGY | 2005年 / 64卷 / 05期

关键词：

D O I：

10.1212/01.WNL.0000153570.33845.6A

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors studied the tolerability of subcutaneous interferon beta-1a (IFNbeta-1a) in 51 patients with early-onset multiple sclerosis. The most frequent systemic adverse effects were flu-like symptoms in 65%. Laboratory abnormalities included asymptomatic leukopenia (27%) and elevated hepatic transaminases (35%). Treatment with IFNbeta-1a was safe and well tolerated in the majority of children and adolescents.

引用

页码：888 / 890

页数：3

共 10 条

[1] Early onset multiple sclerosis - A longitudinal study [J].

Boiko, A ;

Vorobeychik, G ;

Paty, D ;

Devonshire, V ;

Sadovnick, D .

NEUROLOGY, 2002, 59 (07) :1006-1010

[2] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[3]

Francis G, 2001, NEUROLOGY, V56, P1628

[4] Hepatic reactions during treatment of multiple sclerosis with interferon-β-1a -: Incidence and clinical significance [J].

Francis, GS ;

Grumser, Y ;

Alteri, E ;

Micaleff, A ;

O'Brien, F ;

Alsop, J ;

Moraga, MS ;

Kaplowitz, N .

DRUG SAFETY, 2003, 26 (11) :815-827

[5] MULTIPLE-SCLEROSIS IN CHILDHOOD - REPORT OF 15 CASES [J].

HANEFELD, F ;

BAUER, HJ ;

CHRISTEN, HJ ;

KRUSE, B ;

BRUHN, H ;

FRAHM, J .

BRAIN & DEVELOPMENT, 1991, 13 (06) :410-416

[6] Interferon-β treatment in patients with childhood onset multiple sclerosis [J].

Mikaelloff, Y ;

Moreau, T ;

Debouverie, M ;

Pelletier, J ;

Lebrun, C ;

Gout, O ;

Pedespan, JM ;

Van Hulle, C ;

Vermersch, P ;

Ponsot, G .

JOURNAL OF PEDIATRICS, 2001, 139 (03) :443-446

[7] NEW DIAGNOSTIC-CRITERIA FOR MULTIPLE-SCLEROSIS - GUIDELINES FOR RESEARCH PROTOCOLS [J].

POSER, CM ;

PATY, DW ;

SCHEINBERG, L ;

MCDONALD, WI ;

DAVIS, FA ;

EBERS, GC ;

JOHNSON, KP ;

SIBLEY, WA ;

SILBERBERG, DH ;

TOURTELLOTTE, WW .

ANNALS OF NEUROLOGY, 1983, 13 (03) :227-231

[8] Course and prognosis in early-onset MS - Comparison with adult-onset forms [J].

Simone, IL ;

Carrara, D ;

Tortorella, C ;

Liguori, M ;

Lepore, V ;

Pellegrini, F ;

Bellacosa, A ;

Ceccarelli, A ;

Pavone, I ;

Livrea, P .

NEUROLOGY, 2002, 59 (12) :1922-1928

[9] Interferon beta-1a in children with multiple sclerosis is well tolerated [J].

Waubant, E ;

Hietpas, J ;

Stewart, T ;

Dyme, Z ;

Herbert, J ;

Lacy, J ;

Miller, C ;

Rensel, M ;

Schwid, S ;

Goodkin, D .

NEUROPEDIATRICS, 2001, 32 (04) :211-213

[10]

World Health Organization, 1979, WHO HDB REP RES CANC

← 1 →